Abbott and Insulet announce major diabetes technology partnership
Two leading companies have announced a major collaboration to create pioneering diabetes technology for the future.
Abbott, the world leader in glucose sensing technology, and Insulet, the global leader in tubeless insulin pumps, are to work together to create a smart and accurate integrated technology that automatically adjusts insulin delivery based on personalised glucose data.
Abbott’s leading continuous glucose monitoring (CGM) technology is set to team up with Insulet’s Omnipod Horizon™ Automated Insulin Delivery System in a bid to offer an accurate, easy-to-use, integrated digital health platform for people with type 1 diabetes.
Controlled through an app on a user’s personal smartphone device – a unique feature that will be offered with the Omnipod Horizon System – the integrated platform will consist of the trusted tubeless insulin delivery Pod and Abbott’s next-generation FreeStyle Libre sensor.
Through a simple, intuitive design, glucose data from the sensor will be sent directly to the Pod that is embedded with an algorithm to automatically adjust insulin delivery – without the need for an additional device, connection or tubing.
This integrated system will be designed to always remain in automated insulin delivery mode and can be controlled through an app on a user’s personal smartphone to manually take a dose of fast-acting insulin, or bolus, before meals for optimal performance. Additionally, the integrated platform is expected to be the first combined system with a fully disposable wearable sensor and pump.
Jared Watkin, senior vice president of Diabetes Care at Abbott, said: “Abbott is focused on creating future-forward health technologies that simplify how people living with diabetes manage their condition so they can live their best lives.
“As diabetes care becomes more interoperable, we’re developing more connected approaches to improve care. Through this partnership, Abbott and Insulet will offer an integrated digital health platform that is simple and accurate and will provide a best-in-class user experience.”
Shacey Petrovic, Insulet’s President and Chief Executive Officer, added: “We are excited to expand our partnership with Abbott by building on our consumer-centric Omnipod Horizon platform, which offers unparalleled simplicity, accuracy, and now sensor choice for consumers.
“As interoperability becomes increasingly important, our approach to automated insulin delivery will change the future of blood glucose management by offering consumers greater choice in algorithms, sensors and overall experience. This collaboration furthers our shared vision to help our consumers put diabetes in the background, so they have more freedom to enjoy life.”
This connected care solution will integrate both the Omnipod Horizon System and FreeStyle Libre sensor data, offering a seamless option that will fit easily into the lives of people with diabetes. With both Insulet’s and Abbott’s ability to sell its products through the pharmacy, users of the integrated platform will benefit from ease of obtaining supplies with an innovative pay-as-you-go model.
The companies plan to combine FreeStyle Libre’s actionable information from glucose data and trends with Insulet’s next-generation automated insulin delivery system. The idea is to offer an easy to use and affordable integrated technology to change the way people living with diabetes who rely on insulin improve their glucose control for better health.